Inside USP: Metrology and USP Dissolution - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Inside USP: Metrology and USP Dissolution
The United States Pharmacopeia emphasizes mechanical calibration and a performance test to esnure integrity of the dissolution procedure.


Pharmaceutical Technology
Volume 3, Issue 32

USP endorses the concept of mechanical calibration (grounded in metrology), conducted at periodic intervals, to ensure that the mechanical components meet specifications and are in a state of control. These mechanical checks, however, are necessary but not sufficient because they ignore the chemical and kinetic aspects of the dissolution procedure, an oversight that is common in most chemical tests. For example, even the best-calibrated high-performance liquid chromatography equipment still needs systems suitability standards to ensure proper performance within and across laboratories. In one of the most common chemical measurement tests performed, pH, it is not sufficient to ensure only that the electronics of the meter (essentially a voltmeter) are functioning. Rather, there must be assurance that the entire system (the meter, the glass electrode, the counter electrode, and the analyst) is performing adequately through the use of pH buffer standard solutions. Traceability, accuracy, and comparability can then be ensured. USP reference standard tablets used in PVT help ensure that the complex character of a dissolution assembly, coupled with an analyst and analytical procedure, act in concert to yield results within and among laboratories with acceptable accuracy and precision.

USP has established that mechanical calibration of a dissolution assembly does not address adequately all factors (e.g., vessel symmetry) that influence dissolution results (9, 13). Recent USP research also leads to the conclusion that the current tolerances and specifications set for mechanical calibration are inadequate and must be tightened (e.g., 7, 9). Even if mechanical calibration could be brought to complete realization (i.e., control of all possible impacting factors through conformance to specified tolerances), a PVT would still be needed to test the system as a whole and in actual use. Control of each factor individually might be possible, but that would not mean that all elements working in concert would yield reproducible and comparable results.

ISOproficiency . In the terminology of the International Organization for Standardization (ISO), USP's chemical reference standard tablets used in PVT are elements of a proficiency test whereby a laboratory may compare its results to those from other laboratories (18). USP emphasizes the value of these publicly available reference standards that allow PVT within and among laboratories to ensure that all laboratories achieve similar results in the interests of setting a metrologically sound and publicly derived USP performance test in the drug product specification.

GMPs. Ensuring the quality of data generated by analytical equipment includes an overall approach to equipment quality. Pharmaceutical scientists have long accepted that equipment qualification—installation qualification (IQ), operational qualification (OQ), and performance qualification (PQ)—under good manufacturing practices (GMPs) should be executed to verify acceptable quality of output from multicomponent analytical instrumentation. Although practitioners may debate where in the IQ, OQ, and PQ process individual qualification activities should take place, the fundamental principles are indisputable. Each component of the verification process contributes to overall quality of data generated from multicomponent analytical instrumentation, and omission of any component will compromise the quality assurance of data (19). On the basis of its research, USP concludes that mechanical calibration must be coupled with PVT to satisfy GMP requirements for OQ and PQ, respectively.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Source: Pharmaceutical Technology,
Click here